CompanyGraph
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
600671 · SSE · China
hztmyy.comFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleRevenue is $30.99M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 4.71: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.90BCNY433.54M · vs all stocks (USD)
Trailing P/E
205.55xRevenue (TTM)
207.51MCNY30.99M · vs all stocks (USD)
Profit Margin
6.59%Beta
0.0300xvs all stocks
52-Week Change
28.17%vs all stocks
Market Capitalization
2.90BCNY433.54M · vs all stocks (USD)
Enterprise Value
2.90BCNY432.35M · vs all stocks (USD)
Trailing P/E
205.55xForward P/E
188.42xPrice to Sales (TTM)
13.27xPrice to Book (MRQ)
35.95xEnterprise to Revenue
13.95xEnterprise to EBITDA
94.34xGross Margin
46.85%Profit Margin
6.59%Operating Margin
4.82%Return on Assets (TTM)
2.36%Return on Equity (TTM)
5.98%Revenue (TTM)
207.51MCNY30.99M · vs all stocks (USD)
Revenue per Share (TTM)
1.70CNYUpdated Sep 21, 2026Quarterly Revenue Growth
7.10%Gross Profit (TTM)
106.84MCNY15.95M · vs all stocks (USD)
EBITDA (TTM)
21.70MCNY3.24M · vs all stocks (USD)
Net Income (TTM)
13.68MCNY2.04M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-51.80%Operating Cash Flow (TTM)
46.95MCNY7.01M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
20.30MCNY3.03M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
23.99MCNYFY2025 · Dec 31, 2025Revenue
211.75MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
110.61MCNYFY2025 · Dec 31, 2025Gross Profit
101.14MCNYFY2025 · Dec 31, 2025Operating Income
17.17MCNY2.56M · vs all stocks (USD)
Pre-tax Income
10.22MCNYFY2025 · Dec 31, 2025Income Tax Expense
3.02MCNYFY2025 · Dec 31, 2025Net Income
7.20MCNYFY2025 · Dec 31, 2025EBIT
17.42MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
45.45MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
25.06MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.82MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
138.60KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
7.20MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1447CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1447CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
121.79MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
121.79MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
7.20MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-10.94MCNYFY2025 · Dec 31, 2025Free Cash Flow
-42.10MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
26.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
7.20MCNYFY2025 · Dec 31, 2025Other Non-cash Items
19.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-50.12MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.22MCNYFY2025 · Dec 31, 2025Capital Expenditures
-31.15MCNYFY2025 · Dec 31, 2025Sale of Investments
3.99KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-31.15MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
162.14MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-144.73MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-6.50MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.74MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.83MCNYFY2025 · Dec 31, 2025Shares Outstanding
121.78MSharesUpdated Sep 21, 2026Float Shares
43.92MSharesUpdated Sep 21, 2026% Held by Insiders
55.13%vs all stocks
% Held by Institutions
1.35%vs all stocks
Total Cash (MRQ)
70.11MCNY10.47M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5760CNYUpdated Sep 21, 2026Total Debt (MRQ)
189.30MCNY28.27M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.91xCurrent Ratio (MRQ)
0.8400xBook Value per Share (MRQ)
0.6290CNYUpdated Sep 21, 2026Total Assets
442.03MCNY66.01M · vs all stocks (USD)
Total Current Assets
228.48MCNYFY2025 · Dec 31, 2025Total Liabilities
348.04MCNYFY2025 · Dec 31, 2025Total Non-current Assets
213.55MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
65.62MCNYFY2025 · Dec 31, 2025Total Current Liabilities
282.42MCNYFY2025 · Dec 31, 2025Cash
27.62MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.27MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
31.89MCNYFY2025 · Dec 31, 2025Accounts Receivable
143.84MCNYFY2025 · Dec 31, 2025Inventory
39.18MCNYFY2025 · Dec 31, 2025Accounts Payable
80.90MCNYFY2025 · Dec 31, 2025Short-term Debt
157.60MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.58MCNYFY2025 · Dec 31, 2025Long-term Debt
8.65MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.36MCNYFY2025 · Dec 31, 2025Common Stock (Book)
121.78MCNYFY2025 · Dec 31, 2025Retained Earnings
-238.74MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
93.99MCNY14.04M · vs all stocks (USD)
52-Week Low
15.70CNYUpdated Sep 21, 202652-Week High
24.25CNYUpdated Sep 21, 202652-Week Change
28.17%vs all stocks
Beta
0.0300xvs all stocks
50-Day MA
21.26CNYUpdated Sep 21, 2026200-Day MA
19.63CNYUpdated Sep 21, 2026Avg 10-Day Volume
2.76MSharesUpdated Sep 21, 2026Avg 30-Day Volume
3.54MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.1100CNYUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.47Profit Margin: 0.07
Financial Health
Altman Z-Score 4.71: safe zoneNotable
Altman Z-Score: 4.71
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Revenue is $30.99M, lower than 95% of all stocks globallySignificant
Revenue (USD): 30,987,633.16Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Baolingbao Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Staffline Group plc
1 interpretationReceivables Heavy and Growing
Stagwell Inc.
1 interpretationReceivables Heavy and Growing
Greenply Industries Ltd.
1 interpretationReceivables Heavy and Growing